Showing 2221-2230 of 2318 results for "".
- Promius Pharma Introduces Zenatane and “The Promius Promise”https://practicaldermatology.com/news/20130412-promius_pharma_introduces_zenatane_and_the_promius_promise/2459565/Promius Pharma, LLC announced the introduction of Zenatane (Isotretinoin) Capsules, a newly approved isotretinoin option for patients with severe, recalcitrant, nodular acne. Zenatane will be supported by The Promius Promise, a pharmacy serv
- “Dermatologist from the Heart” Program Seeks Grant Proposalshttps://practicaldermatology.com/news/20130410-dermatologist_from_the_heart_program_seeks_grant_proposals/2459567/“Dermatologist from the Heart” is a new program from La Roche-Posay that aims to support initiatives designed to enhance the quality of life for patients. The initiative will award a grant to the most compassionate project spearheaded by dermatologists that seek to enhance patients' quality of life.
- OPTiM Trial Results: New Immunotherapy Study in Melanomahttps://practicaldermatology.com/news/20130409-optim_trial_results_new_immunotherapy_study_in_melanoma/2459569/Results from the Oncovex (GM-CSF) Pivotal Trial in Melanoma (OPTiM) show that a genetically modified version of herpes simplex virus type 1, designated talimogene laherparepvec (T-VEC), shrank melanoma in patients who were in the late stages of the disease. The T-VEC virus works through direct dest
- Rosacea Hinders Social Experiences For More Than 16 Million Americanshttps://practicaldermatology.com/news/20130409-rosacea_hinders_social_experiences_for_more_than_16_million_americans/2459570/Roughly half of rosacea patients refuse certain foods and drinks for fear of triggering a rosacea flare-up. That's according to numbers from the National Rosacea Society (NRS), which designated the month of April as Rosacea Awareness Month to alert the public to the early warning signs of rosacea. T
- Novan Therapeutics: Nitric Oxide May Inhibit Skin Steroidogenesis Locallyhttps://practicaldermatology.com/news/20130408-novan_therapeutics_nitric_oxide_may_inhibit_skin_steroidogenesis_locally/2459571/Novan Therapeutics reports topical nitric oxide-based therapies may reduce androgen levels in the skin by locally inhibiting skin steroidogenesis. The targeted reduction of androgens in the skin could lead to first-in-class local antiandrogen products to treat acne and androgenic alopecia (male patt
- Merz to Absorb Costs of New Excise Tax on Certain Medical Deviceshttps://practicaldermatology.com/news/20130321-merz_to_absord_costs_of_new_excise_tax_on_medical_devices/2459580/Merz Aesthetics announced that it does not intend to raise prices on medical devices, despite the new excise tax on the sale of certain medical devices of about 2.3 percent now going into effect, per the Patient Protection and Affordable Care Act. In a statement to clients and potential clients, Mer
- Cynthia Nixon Partners with Galderma and the NRS to Raise Awareness for Rosaceahttps://practicaldermatology.com/news/20130314-cynthia_nixon_partners_with_galderma_and_the_nrs_to_raise_awareness_for_rosacea/2459591/Actress Cynthia Nixon recently joined with dermatologists Rick Fried, MD and Flor Mayoral, MD and a panel of other experts at the "Face to Face with Rosacea: Empowering Professionals and Patients" educational event at the AAD Meeting in Miami. Sponsored by Galderma in conjunction with the National R
- Galderma Launches Online Epiduo Adherence Programhttps://practicaldermatology.com/news/20130312-galderma_launches_online_epiduo_adherence_program/2459593/Galderma announced its new Epiduo TAP (Treatment, Adherence, and Performance) Program, an online and mobile patient platform that educates acne patients ages 13 and older about the proper application of Epiduo (adapalene and benzoyl peroxide 0.1%/2.5%) Gel and encourages acne patients to stay adhere
- Apremilast Phase III Results Show Efficacy Over Time for Psoriasishttps://practicaldermatology.com/news/20130311-apremilast_phase_iii_results_show_efficacy_over_time_for_psoriasis/2459597/Results from a new Phase III study presented at the AAD Meeting in Miami demonstrate the efficacy of the oral molecule apremilast (Celgene) in psoriasis patients. The ESTEEM 1 study evaluated efficacy and safety in a range of patients, approximately one-third of which was systemic and/or phototherap
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treat